Our results indicate that an AURKA inhibitor (alisertib) and an EZH2 inhibitor (gambogenic) can obviously inhibit the proliferation, migration, and invasion of HCC cells, which are potential targets for clinical application. The gene discussed is AURKA; the disease is hepatocellular carcinoma.